LMAT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

LM

Mkt Cap

$1.85B

Volume

228.40K

Next Earnings

November 4th

Loading chart

LM

LMATLeMaitre Vascular, Inc.

LMAT

Pay with—

Available Balance0.00

LM

Mkt Cap

$1.90B

Volume

228.40K

Next Earnings

November 4th

Chart Financials Earnings News About Dividends Insider Filings

LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026LeMaitre Vascular, Inc. announced it will release its third quarter 2026 financial results on November 4, 2026, after market close, followed by a conference call at 5:00 PM EST to discuss results, business highlights, and company outlook.GlobeNewswire Inc. · Oct 12, 2026

PAHC or LMAT: Which Is the Better Value Stock Right Now?In a comparison of two Medical-Products sector stocks, Phibro Animal Health (PAHC) emerges as the superior value investment option compared to LeMaitre Vascular (LMAT). PAHC holds a Zacks Rank of #2 (Buy) with a Value grade of A, featuring a forward P/E of 11.20 and PEG ratio of 1.13. LMAT, rated #4 (Sell) with a Value grade of D, has a forward P/E of 28.10 and PEG ratio of 2.34, indicating it is relatively overvalued.Zacks Investment Research · Sep 2, 2026

LeMaitre Q1 2026 Financial ResultsLeMaitre Vascular reported Q1 2026 sales of $66.6mm (+11% organic growth) with gross margin expanding 350 bps to 72.7% and EPS growing 42% to $0.68. The company raised full-year 2026 guidance to $280mm sales (+12%) and $3.00 EPS (+26% adjusted). Strong performance was driven by Artegraft growth of 36%, geographic expansion, and operating leverage. The board approved a $0.25/share quarterly dividend and authorized a $100mm share repurchase program.Benzinga · May 5, 2026

LeMaitre Vascular Up 30% as Insider Sells $285K in Stock. Here's What Investors Should KnowLeMaitre Vascular's Senior VP of Operations sold $285,000 in stock (2,625 shares) on March 11, 2026, representing 28.22% of his direct holdings. The sale appears to be a routine option-driven liquidity event rather than a red flag, as the company reported strong Q4 results with 16% sales growth, 47% operating income increase, raised its dividend by 25%, and initiated a $100 million buyback program. The stock has surged 30% over the past year driven by improved margins and consistent demand.The Motley Fool · Mar 28, 2026

LeMaitre to Participate at Upcoming Investor Conferences in MarchLeMaitre Vascular announced its participation in five investor conferences scheduled for March 2026, including presentations at the Leerink Partners Global Healthcare Conference, Citizens Life Sciences Conference, and KeyBanc Capital Markets Healthcare Forum, as well as 1x1 meetings at the Barclays Annual Global Healthcare Conference and ROTH Conference.GlobeNewswire Inc. · Feb 27, 2026

LeMaitre Will Announce Third Quarter 2025 Earnings Results on November 6, 2025LeMaitre Vascular will release its third quarter 2025 financial results on November 6, 2025, after market close, with a conference call scheduled for 5:00 PM EST to discuss results and company outlook.GlobeNewswire Inc. · Oct 9, 2025

LeMaitre (LMAT) Q2 Revenue Jumps 15%LeMaitre Vascular reported strong Q2 2025 financial results, with GAAP revenue of $64.2 million, exceeding estimates and growing 15% year-over-year. The company saw significant growth in catheters and grafts, expanded gross margins to 70%, and raised full-year guidance.The Motley Fool · Aug 6, 2025

Anteris Appoints David Roberts and Gregory Moss to its Board of DirectorsAnteris Technologies Global Corp. announced the appointments of David Roberts and Gregory Moss to its Board of Directors, as the company transitions to its next phase of growth with the upcoming global pivotal PARADIGM study for its DurAVR® Transcatheter Heart Valve.GlobeNewswire Inc. · Jun 10, 2025

LeMaitre Vascular Announces Proposed Convertible Senior Notes OfferingLeMaitre Vascular, Inc. announced its intention to offer $150 million aggregate principal amount of Convertible Senior Notes due 2030 in a private offering. The company plans to use the net proceeds for working capital and general purposes, including potential acquisitions.GlobeNewswire Inc. · Dec 16, 2024

LeMaitre to Participate at Upcoming Investor Conferences in NovemberLeMaitre Vascular, a provider of devices for peripheral vascular disease, announced that its President, David Roberts, will present at three upcoming investor conferences in November 2024.GlobeNewswire Inc. · Nov 1, 2024

to start trading

LM

LMATLeMaitre Vascular, Inc.

LMAT

Pay with—

Available Balance0.00

Your PositionYou don't own any LMAT yet.

Related Tickers

Earnings

Dividends

Last · Aug 20Quarterly

Amount$0.25

Yield1.18%

Annual$0.95